Circulating pentraxin-3 and preeclampsia: a meta-analysis of 17 case-control studies

References

• Dymara-Konopka W, Laskowska M, Oleszczuk J. Preeclampsia – current management and future approach. Curr Pharm Biotechnol. 2018;19(10):786–796.
   PubMed Web of Science ®Google Scholar
• Mayrink J, Costa ML, Cecatti JG. Preeclampsia in 2018: revisiting concepts, physiopathology, and prediction. ScientificWorldJournal. 2018;2018:1.
   Google Scholar
• Karumanchi SA, Granger JP. Preeclampsia and pregnancy-related hypertensive disorders. Hypertension. 2016;67(2):238–242.
   PubMed Web of Science ®Google Scholar
• Mol BWJ, Roberts CT, Thangaratinam S, et al. Pre-eclampsia. Lancet. 2016;387(10022):999–1011.
   PubMed Web of Science ®Google Scholar
• Gamble DT, Brikinns B, Myint PK, et al. Hypertensive disorders of pregnancy and subsequent cardiovascular disease: current national and international guidelines and the need for future research. Front Cardiovasc Med. 2019;6:55.
   PubMed Web of Science ®Google Scholar
• De Kat AC, Hirst J, Woodward M, et al. Prediction models for preeclampsia: a systematic review. Preg Hypertens. 2019;16:48–66.
   Web of Science ®Google Scholar
• Phipps E, Prasanna D, Brima W, et al. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin J Am Soc Nephrol. 2016;11(6):1102–1113.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Chaemsaithong P, Yeo L, et al. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014;10(8):466–480.
   PubMed Web of Science ®Google Scholar
• Das UN. Cytokines, angiogenic, and antiangiogenic factors and bioactive lipids in preeclampsia. Nutrition. 2015;31(9):1083–1095.
   PubMed Web of Science ®Google Scholar
• Casula M, Montecucco F, Bonaventura A, et al. Update on the role of PENTRAXIN 3 in atherosclerosis and cardiovascular diseases. Vascul Pharmacol. 2017;99:1–12.
   PubMed Web of Science ®Google Scholar
• Presta M, Foglio E, Churruca Schuind A, et al. Long Pentraxin-3 modulates the angiogenic activity of fibroblast growth Factor-2. Front Immunol. 2018;9:2327.
   PubMed Web of Science ®Google Scholar
• Zlibut A, Bocsan IC, Agoston-Coldea L. Pentraxin-3 and endothelial dysfunction. Adv Clin Chem. 2019;91:163–179.
   PubMed Web of Science ®Google Scholar
• Ketter P, Yu JJ, Cap AP, et al. PENTRAXIN 3: an immune modulator of infection and useful marker for disease severity assessment in sepsis. Expert Rev Clin Immunol. 2016;12(5):501–507.
   PubMed Web of Science ®Google Scholar
• Giacomini A, Ghedini GC, Presta M, et al. Long PENTRAXIN 3: a novel multifaceted player in cancer. Biochim Biophys Acta Rev Cancer. 2018;1869(1):53–63.
   PubMed Web of Science ®Google Scholar
• Ristagno G, Fumagalli F, Bottazzi B, et al. PENTRAXIN 3 in cardiovascular disease. Front Immunol. 2019;10:823.
   PubMed Web of Science ®Google Scholar
• Cetin I, Cozzi V, Pasqualini F, et al. Elevated maternal levels of the long PENTRAXIN 3 (PTX3) in preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2006;194(5):1347–1353.
   PubMed Web of Science ®Google Scholar
• Rovere-Querini P, Antonacci S, Dell’Antonio G, et al. Plasma and tissue expression of the long PENTRAXIN 3 during normal pregnancy and preeclampsia. Obstet Gynecol. 2006;108(1):148–155.
   PubMed Web of Science ®Google Scholar
• Akolekar R, Casagrandi D, Livanos P, et al. Maternal plasma PENTRAXIN 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009;29(10):934–938.
   PubMed Web of Science ®Google Scholar
• Cetin I, Cozzi V, Papageorghiou AT, et al. First trimester PTX3 levels in women who subsequently develop preeclampsia and fetal growth restriction. Acta Obstet Gynecol Scand. 2009;88(7):846–849.
   PubMed Web of Science ®Google Scholar
• Galbiati S, Causarano V, Pinzani P, et al. Evaluation of a panel of circulating DNA, RNA and protein potential markers for pathologies of pregnancy. Clin Chem Lab Med. 2010;48(6):791–794.
   PubMed Web of Science ®Google Scholar
• Boij R, Svensson J, Nilsson-Ekdahl K, et al. Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia. Am J Reprod Immunol. 2012;68(3):258–270.
   PubMed Web of Science ®Google Scholar
• Cozzi V, Garlanda C, Nebuloni M, et al. PTX3 as a potential endothelial dysfunction biomarker for severity of preeclampsia and IUGR. Placenta. 2012;33(12):1039–1044.
   PubMed Web of Science ®Google Scholar
• Hamad RR, Eriksson MJ, Berg E, et al. Impaired endothelial function and elevated levels of PENTRAXIN 3 in early-onset preeclampsia. Acta Obstet Gynecol Scand. 2012;91(1):50–56.
   PubMed Web of Science ®Google Scholar
• Zhou P, Luo X, Qi HB, et al. The expression of PENTRAXIN 3 and tumor necrosis factor-alpha is increased in preeclamptic placental tissue and maternal serum. Inflamm Res. 2012;61(9):1005–1012.
   PubMed Web of Science ®Google Scholar
• Algeri P, Ornaghi S, Bernasconi DP, et al. Feto-maternal correlation of PTX3, sFlt-1 and PlGF in physiological and pre-eclamptic pregnancies. Hypertens Preg. 2014;33(3):360–370.
   PubMed Web of Science ®Google Scholar
• Estensen ME, Grindheim G, Remme EW, et al. Elevated inflammatory markers in preeclamptic pregnancies, but no relation to systemic arterial stiffness. Preg Hypertens. 2015;5(4):325–329.
   Web of Science ®Google Scholar
• Turkmen O, Mollaoglu S, Goynumer G, et al. Plasma PENTRAXIN 3 levels in preeclamptic patients Clin Exp Obstet Gynecol. 2015;42(2):220–223.
   Google Scholar
• Akhter T, Wikström AK, Larsson M, et al. Serum PENTRAXIN 3 is associated with signs of arterial alteration in women with preeclampsia. Int J Cardiol. 2017;241:417–422.
   PubMed Web of Science ®Google Scholar
• Cakmak HA, Dincgez Cakmak B, Abide Yayla C, et al. Assessment of relationships between novel inflammatory markers and presence and severity of preeclampsia: epicardial fat thickness, pentraxin-3, and neutrophil-to-lymphocyte ratio. Hypertens Preg. 2017;36(3):233–239.
   PubMed Web of Science ®Google Scholar
• Luo Q, Han X. Second-trimester maternal serum markers in the prediction of preeclampsia. J Perinat Med. 2017;45(7):809–816.
   PubMed Web of Science ®Google Scholar
• Cui L, Shu C, Liu Z, et al. Serum protein marker panel for predicting preeclampsia. Preg Hypertens. 2018;14:279–285.
   Web of Science ®Google Scholar
• Garg P, Jaryal AK, Kachhawa G, et al. Estimation of asymmetric dimethylarginine (ADMA), placental growth factor (PLGF) and PENTRAXIN 3 (PTX 3) in women with preeclampsia. Preg Hypertens. 2018;14:245–251.
   Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.
   PubMed Web of Science ®Google Scholar
• Higgins J, Green S. [Internet]. 2011. Cochrane handbook for systematic reviews of interventions Version 5.1.0. The Cochrane Collaboration. 2011. Available from: www.cochranehandbook.org.
   Google Scholar
• ACOG Committee on Practice Bulletins–Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol. 2002;(33):159–167.
   PubMedGoogle Scholar
• Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Preg. 2001;20(1):IX–XIV.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; [Internet]; 2010. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statist Med. 2002;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013;209(6):544.e1–544.e12.
   PubMed Web of Science ®Google Scholar
• Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv. 2011;66(8):497–506.
   PubMed Web of Science ®Google Scholar
• Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Yano Y, Hatakeyama K. Inflammation and hypertension: new clinical information on pentraxin-3. Anadolu Kardiyol Derg. 2012;12(4):305–306.
   PubMed Web of Science ®Google Scholar
• Gustin C, Delaive E, Dieu M, et al. Upregulation of pentraxin-3 in human endothelial cells after lysophosphatidic acid exposure. Arterioscler Thromb Vasc Biol. 2008;28(3):491–497.
   PubMed Web of Science ®Google Scholar
• Hill AL, Lowes DA, Webster NR, et al. Regulation of pentraxin-3 by antioxidants. Br J Anaesth. 2009;103(6):833–839.
   PubMed Web of Science ®Google Scholar
• Carrizzo A, Lenzi P, Procaccini C, et al. PENTRAXIN 3 induces vascular endothelial dysfunction through a p-selectin/matrix metalloproteinase-1 pathway. Circulation. 2015;131(17):1495. discussion 1505.
   PubMed Web of Science ®Google Scholar
• Leali D, Inforzato A, Ronca R, et al. Long PENTRAXIN 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis. Arterioscler Thromb Vasc Biol. 2012;32(3):696–703.
   PubMed Web of Science ®Google Scholar
• O’Neill CL, Guduric-Fuchs J, Chambers SE, et al. Endothelial cell-derived PENTRAXIN 3 limits the vasoreparative therapeutic potential of circulating angiogenic cells. Cardiovasc Res. 2016;112(3):677–688.
   PubMed Web of Science ®Google Scholar
• Makarewicz-Wujec M, Parol G, Parzonko A, et al. Supplementation with omega-3 acids after myocardial infarction and modification of inflammatory markers in light of the patients’ diet: a preliminary study. Kardiol Pol. 2017;75(7):674–681.
   PubMed Web of Science ®Google Scholar